Evidence map›Paper›PMID 40149886›Full record

ArticleBiomolecules2025

Ru(II) Complexes with 3,4-Dimethylphenylhydrazine: Exploring In Vitro Anticancer Activity and Protein Affinities.

Jasmina Dimitrić Marković, Dušan Dimić, Thomas Eichhorn, Dejan Milenković, Aleksandra Pavićević, Dragoslava Đikić, Emilija Živković, Vladan Čokić, Tobias Rüffer, Goran N Kaluđerović

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jasmina Dimitrić MarkovićFaculty of Physical Chemistry, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0003-4796-6251
Dušan DimićFaculty of Physical Chemistry, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0001-8127-5396
Thomas EichhornDepartment of Engineering and Natural Sciences, University of Applied Sciences Merseburg, D-06217 Merseburg, Germany.ORCID 0000-0002-6302-1357
Dejan MilenkovićDepartment of Science, Institute for Information Technologies, University of Kragujevac, 34000 Kragujevac, Serbia.
Aleksandra PavićevićFaculty of Physical Chemistry, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-1784-2859
Dragoslava ĐikićInstitute for Medical Research, University of Belgrade, 11000 Belgrade, Serbia.
Emilija ŽivkovićInstitute for Medical Research, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-6305-8205
Vladan ČokićInstitute for Medical Research, University of Belgrade, 11000 Belgrade, Serbia.ORCID 0000-0002-0362-1449
Tobias RüfferInstitute of Chemistry, Chemnitz University of Technology, Straße der Nationen 62, D-09111 Chemnitz, Germany.
Goran N KaluđerovićDepartment of Engineering and Natural Sciences, University of Applied Sciences Merseburg, D-06217 Merseburg, Germany.ORCID 0000-0001-5168-1000

Funding

Ministry of Science, Technological Development and Innovation, Serbia 451-03-65/2024-03/200146
6 · The paper itself

Abstract

Two new Ru(II) complexes, mononuclear [RuCl

Indexed as

Antineoplastic AgentsCoordination ComplexesHydrazinesRutheniumApoptosisCell Line, TumorCell SurvivalHumansMatrix Metalloproteinase 9Molecular Docking SimulationProtein BindingAntineoplastic AgentsCoordination ComplexesHydrazinesMatrix Metalloproteinase 9Rutheniumcell cycleHSAMDA/PC levelsMIA PaCa-2/MDA-MB-231/HS-5 cellsRu(II) complexesspin-probing

Identifiers

PMID40149886
PMCPMC11940238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.